TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24717377
Drug: Choice of
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of treatment
Study: 30672067
Drug: IVIG restabilization
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG restabilization with an induction dose of 2 g/kg bodyweight (bw) IgPro10 (Privigen) and maintenance doses of 1 g/kg bw every 3 weeks for up to 13 weeks
Study: 27399131
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (ticagrelor and apixaban)
Study: 27399131
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (ticagrelor and apixaban with acetylsalicylic acid)
Study: 16564798
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg daily)
Study: 12626213
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg daily)
Study: 20715300
Drug: Mirtazapine (30‐45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30‐45 mg/day)
Study: 17383923
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point injection
Study: 12416546
Drug: Local chemotherapy
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local chemotherapy with cisplatin-depot (CDDP-D)
Study: 10451136
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg x kg(‐1) p.o. 30 min before anesthesia)
Study: 1522840
Drug: Standard-dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epinephrine (1 mg)
Study: 2038933
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine (5 mg)
Study: 1315346
Drug: NaF rinse
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaF rinse (12 mmol/L)
Study: 1315346
Drug: Two-solution F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-solution F rinse (12 mmol/L)
Study: 1315346
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pH 7 remineralizing solution)
Study: 18815727
Drug: Paracetamol 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1,000 mg - Caffeine 130 mg (PCF)
Study: 18815727
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg (NAP)
Study: 16807444
Drug: Gemcitabine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 300 mg/m(2) administered during 1 h infusion
Study: 16807444
Drug: Gemcitabine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 300 mg/m(2) administered during 2 h infusion
Study: 16807444
Drug: Gemcitabine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 300 mg/m(2) administered during 3 h infusion
Study: 16807444
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m(2) administered during 30 min infusion
Study: 12669262
Drug: Creatine-pyruvate (Cr(pyr),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine-pyruvate (Cr(pyr), 2 x 3.5 g x d‐1)
Study: 7960690
Drug: Moderate exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate exercise training (45 min, 3 times weekly for 12 weeks)
Study: 2884861
Drug: Doxazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (mean dosage 6.9 mg, range 1 to 16)
Study: 2884861
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) (mean dosage 84.6 mg, range 25 to 100)
Study: 27389084
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg twice daily
Study: 12237201
Drug: Magnesium-lignocaine (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-lignocaine (20% magnesium sulphate 500 mg + lignocaine 1% 75 mg)
Study: 12237201
Drug: Lignocaine alone
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine alone (1% 75 mg)
Study: 8009327
Drug: Functional restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional restoration treatment at two clinics
Study: 8009327
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no functional restoration treatment)
Study: 8009327
Drug: Functional restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional restoration treatment
Study: 26087107
Drug: Hange-Shashin-To (HST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hange-Shashin-To (HST) 5.0 g mixed with jelly
Study: 23618760
Drug: VSL#3 (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3 (one sachet twice daily for the length of the antibiotics course and for seven days thereafter)
Study: 23618760
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one sachet twice daily for the length of the antibiotics course and for seven days thereafter)
Study: 16778264
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 mcg qd for children < 11 years old and 400 mcg qd for others)
Study: 15117980
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² intravenously (i.v.) day 1 with vitamin B12, folic acid, and dexamethasone
Study: 15117980
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² i.v. day 1 with dexamethasone
Study: 9623901
Drug: Bioerodible tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bioerodible tetracycline gel
Study: 2492674
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 100 micrograms LT4 and 100 micrograms iodide
Study: 28592515
Drug: Lysine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine (5 or 10 g l-lysine)
Study: 26010632
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone supplement (100 mg of total isoflavones, n=193)
Study: 26010632
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone supplement
Study: 21900836
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 IV, gemcitabine 1500 mg/m2 IV, and bevacizumab 10 mg/kg IV (days 1 and 15 of 28‐day cycles)
Study: 21900836
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 IV, carboplatin AUC=5 IV, and bevacizumab 15 mg/kg IV (day 1 of 21‐day cycles)
Study: 19328723
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with platelet counts < 100 x 10(9)/L
Study: 2720578
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine sulfate preparation (MS Contin tablets) administered every 12 hours
Study: 2720578
Drug: Morphine oral
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine oral solution (MOS) administered every 4 hours
Study: 29745627
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) for two weeks
Study: 24204744
Drug: MEDI‐559 (live
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI‐559 (live attenuated intranasal vaccine)
Study: 21914136
Drug: Tadalafil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (40 mg for 6 weeks)
Study: 16407639
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral sustained‐release theophylline plus budesonide (200 microg b.i.d.)
Study: 16407639
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg montelukast plus budesonide (200 microg b.i.d.)
Study: 16407639
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of inhaled budesonide (400 microg b.i.d.)
Study: 14525750
Drug: Computerized ED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized ED discharge instructions with National Highway Traffic Safety Administration recommendations for motor vehicle CRDs
Study: 9170417
Drug: Acute myeloid
Normalized name: A cd33/cd3 bispecific t-cell engager antibody for acute myeloid leukemia therapy
DrugBank: Eluvixtamab (DB17252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute myeloid leukemia with afebrile neutropenia from chemotherapy
Study: 1439640
Drug: Intraaortic protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraaortic protamine administration (group A)
Study: 1439640
Drug: Intravenous protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous protamine administration (group V)
Study: 31615996
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose carbon monoxide exposure (100-200 ppm) for 12 weeks
Study: 30360964
Drug: Ixekizumab Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab Q2W (80 mg subcutaneous every two weeks)
Study: 30360964
Drug: Ixekizumab Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab Q4W (80 mg subcutaneous every four weeks)
Study: 30360964
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg Q2W)
Study: 24452879
Drug: Oxycodone/naloxone prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/naloxone prolonged-release (PR)
Study: 24452879
Drug: Oxycodone/naloxone PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/naloxone PR
Study: 22582911
Drug: Methyl aminolevulinate
Normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl aminolevulinate (MAL) plus red light therapy
Study: 22582911
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus red light therapy
Study: 19620877
Drug: Etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 200 mg twice daily
Study: 15578800
Drug: Academic medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Academic medicine
Study: 7633189
Drug: 0.35 mg
Normalized name: nicotine 0.35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.35 mg kg‐1 day‐1 prednisolone for six months
Study: 1688515
Drug: ThioTEPA (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThioTEPA (30 mg) in distilled water
Study: 1688515
Drug: ThioTEPA (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThioTEPA (30 mg) in 10% (v/v) Tween 80 (30 ml)
Study: 28071
Drug: Penbutolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (40 mg b.i.d.)
Study: 28071
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg b.i.d.)
Study: 25484179
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 800-2400mg, once-daily
Study: 25484179
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 600-1800mg, once-daily
Study: 25484179
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 900mg, once-daily (during recurrence prevention study)
Study: 25484179
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 300, 900, and 1800mg, once-daily (during recurrence prevention study)
Study: 15785941
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol (Calcijex) administered as a bolus injection three times a week for up to 12 weeks, with initial doses of 0.5-1.5 microg based on severity of secondary HPT.
Study: 15785941
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times a week for up to 12 weeks.
Study: 15785941
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol (Calcijex)
Study: 12151929
Drug: TA 50
Normalized name: Denta 5000 Plus
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TA 50 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Study: 12151929
Drug: TA 100
Normalized name: NUCYNTA 100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA 100 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Study: 12151929
Drug: TA 10
Normalized name: Zebeta 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA 10 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Study: 12151929
Drug: Simulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulation of previous studies with a 30‐min loading dose of 12.5 mg/kg and maintenance infusion of 6.5 mg x kg(‐1) x hr(‐1)
Study: 12151929
Drug: Simulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulation of previous studies with a 30 mg/kg loading dose plus 16 mg x kg(‐1) x h(‐1) continuous infusion
Study: 28584913
Drug: Triazolam 0.250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.250 mg
Study: 8824695
Drug: Triazolam 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.375 mg
Study: 6265109
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide (500 mg/m2 I.V.), Adriamycin (50 mg/m2 I.V.), DTIC (250 mg/m2 I.V.), and vincristine (1 mg/m2 I.V.) every 4 weeks for three cycles followed by the same combination every 4 weeks for an additional six cycles.
Study: 6265109
Drug: Non-cross-resistant drug
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-cross-resistant drug combination of BCNU (100 mg/m2 I.V.), procarbazine (100 mg/m2 p.o. daily x 10 days), methotrexate (25 mg/m2 I.V.), and vinblastine (5 mg/m2 I.V.) every 4 weeks for six cycles.
Study: 6265109
Drug: Alternating treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating treatments with the two regimens for a total of six cycles of therapy.
Study: 31544471
Drug: Empirical intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical intravenous vancomycin
Study: 31084291
Drug: NAVIGATE (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAVIGATE (early intervention treatment model)
Study: 28778815
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg/day for 14 days
Study: 23598371
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg candesartan in the first week, and 32 mg candesartan in the second and third week
Study: 6137969
Drug: Midazolam 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.10 mg/kg
Study: 9585306
Drug: Midazolam 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.08 mg/kg
Study: 7664702
Drug: Midazolam 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.06 mg/kg
Study: 9585306
Drug: Midazolam 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.04 mg/kg
Study: 8029790
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (A)
Study: 8029790
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity oral anticoagulation with warfarin (W)
Study: 8029790
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with warfarin and aspirin (WA)
Study: 8029790
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (WA), Warfarin (W), Aspirin (A)
Study: 21668835
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical clindamycin phosphate
Study: 17004893
Drug: B. polyfermenticus
Approvals — FDA: no, EMA: no, PMDA: no
Description: B. polyfermenticus tablets at a dose of 3.1 x 10(8) colony-forming units/day for 8 weeks
Study: 17004893
Drug: B. polyfermenticus
Approvals — FDA: no, EMA: no, PMDA: no
Description: B. polyfermenticus tablets
Study: 10493339
Drug: Reduced osmolarity
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced osmolarity ORS (224 mmol/l)
Study: 10493339
Drug: Standard ORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ORS (311 mmol/l)
Study: 2066768
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg oral dextroamphetamine
Study: 6354828
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of oral omeprazole
Study: 6354828
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of oral omeprazole
Study: 6354828
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of oral omeprazole
Study: 30144099
Drug: Vixotrigine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vixotrigine (400 mg for men, 300 mg for women) administered orally twice daily for 36 days
Study: 30144099
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally twice daily for 36 days
Study: 21986094
Drug: s.c. denosumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. denosumab (120 mg) every 4 weeks
Study: 21986094
Drug: i.v. zoledronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. zoledronic acid (4 mg) every 4 weeks
Study: 19995510
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: bevelling the margins of buccal fissures (0.5 mm bevel) after enameloplasty
Study: 18094378
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg once daily
Study: 18094378
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg once daily
Study: 8340736
Drug: Promethazine 50
Normalized name: promethazine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 50 mg and calcium 1000 mg daily
Study: 8340736
Drug: Calcium 1000
Normalized name: RITE AID Calcium 1000mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1000 mg daily
Study: 23307164
Drug: Dexmedetomidine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.25 μg/kg
Study: 23259263
Drug: Salbutamol aerosol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol aerosol, 200 microg, less than 8 sprays in 24 h
Study: 20009958
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment plus self-care
Study: 1841669
Drug: Propanolol 80
Normalized name: Propanolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propanolol 80 mg
Study: 31584525
Drug: Intralesional saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional saline injection
Study: 26328787
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + Vecuronium
Study: 24849043
Drug: Sublingual testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual testosterone (0.5 mg) followed by buspirone (10 mg) tablet
Study: 24849043
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet of testosterone and buspirone
Study: 14597456
Drug: Leech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leech therapy (4 to 6 locally applied leeches)
Study: 14597456
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac therapy (28-day regimen)
Study: 30636672
Drug: Leech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leech therapy
Study: 10748449
Drug: Pretherapeutic hyperprolactinemia
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretherapeutic hyperprolactinemia (PRL >/=15.0 ng/mL)
Study: 3891189
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide gel (30 ml)
Study: 31050156
Drug: Low 1,5-AG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low 1,5-AG level (<39.7 μmol/L)
Study: 16186434
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg DRSP/1 mg E2
Study: 12013355
Drug: Piperacillin 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4.0 g-tazobactam 0.5 g administered every 8 hours
Study: 12013355
Drug: Piperacillin 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 3.0 g-tazobactam 0.375 g administered every 6 hours
Study: 12013355
Drug: Piperacillin 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 3.0 g-tazobactam 0.375 g every 4 hours
Study: 12013355
Drug: Piperacillin 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4.0 g-tazobactam 0.5 g every 6 hours
Study: 12013355
Drug: Continuous-infusion piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous-infusion piperacillin 12 g-tazobactam 1.5 g/day
Study: 10202313
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 6 microm monodisperse Teflon particles labelled with 111In after bronchial provocation with allergen